Effect and mechanism of PCSK9 inhibitors on improving slow flow and myocardial injury during interventional surgery in NSTEMI patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058510

Enrollment

Unknown

Registered

2022-04-10

Start date

2022-05-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-ST elevation myocardial infarction (NSTEMI)

Interventions

Experimental group:Evolocumab

Control group:Standard treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-st-segment elevation acute coronary syndromes (unstable angina or NSTEMI) requiring early (48 hours) coronary angiography.

Exclusion criteria

Exclusion criteria: Non-st-segment elevation acute coronary syndrome in high-risk patients with emergency coronary angiography indications, left ventricular ejection fraction is less than 30%.

Design outcomes

Primary

Measure	Time frame
Proproteininvertase subtilis protease /Kexin9;Low density lipoprotein;Low density lipoprotein receptor;Superoxide dismutase;Malondialdehyde;MAPK pathway;Reactive oxygen species;Ejection fraction;Microcirculation resistance index;	—

Countries

China

Contacts

Public ContactTang Jiong

Fuwai Cardiovascular Hospital of Yunnan Province

3377970@qq.com+86 18602887796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026